language flag

English

  • language flag

    English

  • language flag

    German

  • language flag

    Italian

  • language flag

    Spanish

Therakos Logo - Dark
Languages:
Therakos e-learning platform

WELCOME TO THERAKOS.EU MY AREA

 
email
THANK YOU FOR FILLING OUT OUR REGISTRATION FORM
You will receive an email in the coming days with further information about your application.

CREATE YOUR
MyTHERAKOS ACCOUNT

By registering with MyTHERAKOS, you can take advantage of our event calendar, keep up to date with upcoming webinars and watch those you missed on demand.

If you have a CELLEXTM system, you will also have exclusive access to the E-Learning platform and a dashboard where you can see the status of your orders, operator manuals, technical bulletins and much more.

Registration to MyTHERAKOS is for healthcare professionals only and is not intended for use in the US and Canada.

WHAT’S AVAILABLE IN YOUR MyTHERAKOS ACCOUNT AREA

Live and on-demand webinars, from experienced key opinion leaders. Register for upcoming webinars and quickly review webinars you've already attended.

MEMBER EVENTS

We're more than webinars. The Therakos Institute hosts symposia, centres of excellence, meet and ask the expert sessions. By creating your MyTHERAKOS account, you can access everything easily.

GAIN ACCESS TO EXCLUSIVE CONTENT

We're continually updating content available within MyTHERAKOS, available to any HCP looking to learn more about ECP.

IF YOU HAVE A CELLEXTM PHOTOPHERSIS SYSTEM IN YOUR HEALTHCARE FACILITY, YOU'LL ALSO SEE:
MANAGEMENT DASHBOARD

Handle everything around your system orders in one simple place including service requests and invoices.

E-LEARNING - OPERATOR RESOURCES

Training and materials to operate your CELLEXTM System.

RESOURCE LIBRARY

Our operators resources include reference guides, technical bulletins, training materials and user manuals.

TO CREATE YOUR PROFILE, PLEASE COMPLETE THE FORM BELOW.

Some areas of our site are restricted from the public. Imputing your role will help ensure you are able to view all content relevant to you.

By inputting your country, we can better ensure you are getting access to the content most relevant to you. If you are also an existing customer and have inputted your CELLEXTM System serial number, the CELLEXTM training materials will be available in your local language.

Some areas of our site are restricted from the public and from certain regions. Imputing your institution will help ensure you are able to view all content relevant to you.





PLEASE SELECT AT LEAST ONE OF THE SERVICES BELOW YOU WOULD LIKE TO GET ACCESS TO

*Would you like to sign-up for our Therakos Institute webinars?




*Are you an existing customer?


If you are an existing customer, you can also sign up for MyTherakos.



*Please insert your CELLEXTM System serial number

Required to gain access to CELLEXTM System training and support materials. Your serial number can be found on your instrument.


The serial number can be found on your device





Would you like to be informed via email about all our upcoming events?







*Compulsory fields


You are leaving the THERAKOS.EU website.
Therakos does not review or control the content of non-Therakos websites, and this hyperlink does not constitute an endorsement by Therakos of the site’s content. Therakos privacy procedures do not apply to the owners of a non-Therakos website.

Important Safety Information
For the TherakosTM Photopheresis
Procedure

Indications

The THERAKOSTM CELLEXTM Photopheresis System is indicated for the administration of photopheresis. Please refer to the appropriate product labelling for a complete list of warnings and precautions.

Contraindications

THERAKOSTM Photopheresis is contraindicated in:

  • Patients possessing a specific history of a light sensitive disease.
  • Patients who cannot tolerate extracorporeal volume loss or who have white blood cell counts greater than 25,000 / mm3.
  • Patients who have coagulation disorders or who have previously had a splenectomy.

Warnings and Precautions

THERAKOSTM Photopheresis treatments should always be performed in locations where standard medical emergency equipment is available. Volume replacement fluids and/or volume expanders should be readily available throughout the procedure. Safety in children has not been established.

  • Do not expose the device to a magnetic resonance (MR) environment. The device may present a risk of projectile injury, and thermal injury and burns may occur. The device may generate artifacts in the MR image, or may not function properly.
  • Thromboembolic events, including pulmonary embolism and deep vein thrombosis, have been reported in the treatment of Graft versus Host Disease (GvHD). Special attention to adequate anticoagulation is advised when treating patients with GvHD.
  • When prescribing and administering THERAKOSTM Photopheresis for patients receiving concomitant therapy, exercise caution when changing treatment schedules to avoid increased disease activity that may be caused by abrupt withdrawal of previous therapy.

Adverse Events

  • Hypotension may occur during any treatment involving extracorporeal circulation. Closely monitor the patient during the entire treatment for hypotension.
  • Transient pyretic reactions, 37.7–38.9°C (100–102°F), have been observed in some patients within six to eight hours of reinfusion of the photoactivated leukocyte-enriched blood. A temporary increase in erythroderma may accompany the pyretic reaction.
  • Treatment frequency exceeding labelling recommendations may result in anaemia.
  • Venous access carries a small risk of infection and pain.

Please refer to the THERAKOSTM CELLEXTM Photopheresis System Operator Manual for a complete list of warnings and precautions.

IMPORTANT SAFETY INFORMATION FOR METHOXSALEN USED IN CONJUNCTION WITH THERAKOSTM PHOTOPHERESIS

Contraindications

Methoxsalen is contraindicated in:

  • Patients exhibiting idiosyncratic or hypersensitivity reactions to methoxsalen, psoralen compounds, or any of the excipients
  • Patients with co-existing melanoma, basal cell or squamous cell skin carcinoma
  • Patients who are pregnant, and sexually active men and women of childbearing potential unless adequate contraception is used during treatment
  • Patients with aphakia because of the significantly increased risk of retinal damage due to the absence of a lens

Warnings and Precautions

  • Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents.
  • Oral administration of methoxsalen followed by cutaneous UVA exposure (PUVA therapy) is carcinogenic.
  • Patients should be told emphatically to wear UVA absorbing, wrap-around sunglasses for twenty-four (24) hours after methoxsalen treatment. They should wear these glasses any time they are exposed to direct or indirect sunlight, whether they are outdoors or exposed through a window.
  • Safety in children has not been established.

Refer to the package insert for methoxsalen sterile solution (20 micrograms / mL) or the oral 8-methoxypsoralen dosage formulation for a list of all warnings and precautions.

Please refer to the THERAKOSTM CELLEXTM Photopheresis System Operator Manual for a complete list of warnings, precautions and adverse events.

This website is not intended for healthcare professionals based in US, France and Canada.

Please verify your status below.

I am a healthcare professional and

I am eligible to access this part of the website

I am not a healthcare professional.

I would like to return to the homepage

This website is not intended for residents
based in the US, France or Canada.

PLEASE CLICK HERE TO ENTER

If you are a French resident, please visit www.therakos.fr

Applications for the 2022 EIA are now closed.
The 2022 ECP Immunomodulation Investigator Award has been awarded to Professor Andrew Fisher, Professor of Respiratory Transplant Medicine at Newcastle University, and Honorary Consultant Respiratory and Transplant Physician at The Newcastle upon Tyne Hospitals NHS Foundation Trust's Institute of Transplantation. The objective of his project is to perform an in depth mechanistic assessment of Extracorporeal Photopheresis (ECP) treatment in patients suffering from Chronic lung Allograft Dysfunction (CLAD).

Full details are available on our press release page.

Copy the link to share with the HCP by clicking on the button below

 
THANK YOU FOR YOUR MESSAGE
We will take care of your request and get in contact with you soon
 
THANK YOU FOR YOUR APPLICATION
We can confirm we have received your submission.
 
AUTHORISATION

The Therakos e-learning platform wants to access the following information:

Your basic public profile
Your public email address

Please click the below button to authorise it

WELCOME TO THERAKOS.EU MY AREA
Forgot your password? Click Here
Not yet registered?
WELCOME TO THERAKOS.EU MY AREA
Forgot your password?